Keisuke Miki

Dr. Keisuke Miki

National Hospital Organization Osaka Toneyama Medical Center
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KMKeisuke Miki
Keisuke Miki
RMRyoji Maekura
Ryoji Maekura
NNNoritoshi Nagaya
Noritoshi Nagaya
MNMasamitsu Nakazato
Masamitsu Nakazato
HKHiroshi Kimura
Hiroshi Kimura
KKKenji Kangawa
Kenji Kangawa
Pulmonary cachexia is common in advanced chronic obstructive pulmonary disease (COPD), culminating in exercise intolerance and a poor prognosis. Ghrelin is a novel growth hormone (GH)-releasing peptide with GH-independent effects. The efficacy and safety of adding ghrelin to pulmonary rehabilitation (PR) in cachectic COPD patients were investigated. In a multicenter, randomized, double-blind, placebo-controlled trial, 33 cachectic COPD patients were randomly assigned PR with intravenous ghrelin (2 µg/kg) or placebo twice daily for 3 weeks in hospital. The primary outcomes were changes in 6-min walk distance (6-MWD) and the St. George Respiratory Questionnaire (SGRQ) score. Secondary outcomes included changes in the Medical Research Council (MRC) scale, and respiratory muscle strength. At pre-treatment, serum GH levels were increased from baseline levels by a single dose of ghrelin (mean change, +46.5 ng/ml; between-group p<0.0001), the effect of which continued during the 3-week treatment. In the ghrelin group, the mean change from pre-treatment in 6-MWD was improved at Week 3 (+40 m, within-group p = 0.033) and was maintained at Week 7 (+47 m, within-group p = 0.017), although the difference between ghrelin and placebo was not significant. At Week 7, the mean changes in SGRQ symptoms (between-group p = 0.026), in MRC (between-group p = 0.030), and in maximal expiratory pressure (MEP; between-group p = 0.015) were better in the ghrelin group than in the placebo group. Additionally, repeated-measures analysis of variance (ANOVA) indicated significant time course effects of ghrelin versus placebo in SGRQ symptoms (p = 0.049) and MEP (p = 0.021). Ghrelin treatment was well tolerated. In cachectic COPD patients, with the safety profile, ghrelin administration provided improvements in symptoms and respiratory strength, despite the lack of a significant between-group difference in 6-MWD. UMIN Clinical Trial Registry C000000061

Verified
Journal Article
Open access
PDF file
KFKiyoharu Fukushima
Kiyoharu Fukushima
SKSeigo Kitada
Seigo Kitada
YAYuko Abe
Yuko Abe
YYYuji Yamamoto
Yuji Yamamoto
TMTakanori Matsuki
Takanori Matsuki
HKHiroshi Kida
Hiroshi Kida
Background: Multidrug therapy is essential for preventing respiratory failure in patients with highly progressive Mycobacterium avium complex pulmonary disease (MAC-PD). However, the prognosis and long-term outcome following combination therapy is poorly understood. Methods: We retrospectively evaluated the clinical characteristics and long-term outcomes in patients with chemo-naïve progressive MAC-PD, hospitalized for first-line multidrug therapy. Results: Among 125 patients, 86 (68.8%) received standardized treatment (rifampicin, ethambutol, clarithromycin), 25 (20.0%) received a fluoroquinolone (FQ)-containing regimen, and 53 (42.4%) received aminoglycoside injection. The sputum conversion rate was 80.0%, and was independently associated with standardized treatment. The incidence of refractory disease (45.6%) was independently and negatively associated with standardized regimen and aminoglycoside use. Choice of an FQ-containing regimen was not associated with positive outcome. Clarithromycin resistance occurred in 16.8% and was independently associated with refractory disease. MAC-PD-associated death occurred in 3.3% of patients with non-cavitary nodular bronchiectasis (NB) and 21.3% with cavitary MAC-PD over a median follow-up period of 56.4 months. The rates of MAC-PD-associated death were comparable between cavitary-NB and fibrocavitary disease. Concurrent chronic pulmonary aspergillosis (CPA) occurred in 13 (17.3%) patients with cavitary MAC-PD, and age, diabetes mellitus, and CPA were independent risk factors for mortality. Conclusions: Standardized intensive multidrug treatment reduces disease progression and persistence in progressive MAC-PD. Cavitary NB may differ from, rather than being just an advanced stage of, non-cavitary NB. The high incidence and significant mortality of CPA in cavitary MAC-PD highlight the need for early diagnosis and treatment.

2 September 2009 in Respirology
Verified
Journal Article
Closed access
PDF file
KMKeisuke Miki
Keisuke Miki
RMRyoji Maekura
Ryoji Maekura
THToru Hiraga
Toru Hiraga
HHHisako Hashimoto
Hisako Hashimoto
SKSeigo Kitada
Seigo Kitada
MMMasaharu Motone
Masaharu Motone

10 June 2013 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
KMKeisuke Miki
Keisuke Miki
RMRyoji Maekura
Ryoji Maekura
NNNoritoshi Nagaya
Noritoshi Nagaya
SKSeigo Kitada
Seigo Kitada
MMMari Miki
Mari Miki
KKKenji Kangawa
Kenji Kangawa
The aim of this substudy of the ghrelin treatment, multicenter, randomized, double-blind, placebo-controlled trial was to investigate the effects of ghrelin administration on exercise capacity and the underlying mechanisms in underweight patients with chronic obstructive pulmonary disease (COPD) using cardiopulmonary exercise testing. Twenty underweight COPD patients were randomized to pulmonary rehabilitation with intravenous ghrelin (2 μg/kg, n = 10) or placebo (n = 10) twice daily for 3 weeks in a double-blind fashion. The primary outcome was changes in peak oxygen uptake V • o 2 . Secondary outcomes included changes in exertional cardio-respiratory functions: O2-pulse, physiologic dead space/tidal volume-ratio (VD/VT), ventilatory equivalent for oxygen V • E / V • o 2 , and ventilatory equivalent for carbon dioxide V • E / V • c o 2 . With incremental exercise, at peak exercise, there was a significant difference in the mean difference (ghrelin minus placebo), i.e., treatment effect in: i) peak V • o 2 (1.2 mL/kg/min, 95% CI: 0.2-2.3 mL/kg/min, between-group p = 0.025); ii) V • E / V • o 2 (-4.2, 95% CI: -7.9 to -0.5, between-group p = 0.030); iii) V • E / V • c o 2 (-4.1, 95% CI: -8.2 to -0.1, between-group p = 0.045); iv) VD/VT (-0.04, 95% CI: -0.08 to -0.00, between-group p = 0.041); and v) O2-pulse (0.7 mL/beat, 95% CI: 0.3 to 1.2 mL/beat, between-group p = 0.003). Additionally, repeated-measures analysis of variance (ANOVA) indicated a significant time-course effect of ghrelin versus placebo in the peak V • o 2 (p = 0.025). Ghrelin administration was associated with improved exertional capacity and improvements in ventilatory-cardiac parameters. UMIN (University Hospital Medical Information Network in Japan) C000000061

1 April 2017 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
KMKeisuke Miki
Keisuke Miki
RMRyoji Maekura
Ryoji Maekura
SKSeigo Kitada
Seigo Kitada
MMMari Miki
Mari Miki
KYKenji Yoshimura
Kenji Yoshimura
KIKimiko Inoue
Kimiko Inoue
Background: COPD patients undergoing pulmonary rehabilitation (PR) show various responses. The purpose of this study was to investigate the possible mechanisms and predictors of the response to PR in COPD patients. Methods: Thirty-six stable COPD patients underwent PR including a 4-week high-intensity exercise training program, and they were evaluated by cardiopulmonary exercise testing. All patients (mean age 69 years, severe and very severe COPD 94%) were classified into four groups by whether the exercise time (Tex) or the peak oxygen uptake (VO2) increased after PR: two factors increased (both the Tex and the peak VO2 increased); two factors decreased; time only increased (the Tex increased, but the peak VO2 economized); and VO2 only increased (the Tex decreased, but the peak VO2 increased). Within all patients, the relationships between baseline variables and the post-to-pre-change ratio of the time–slope, Tex/(peak minus resting VO2), were investigated. Results: Compared with the two factors increased group (n=11), in the time only increased group (n=18), the mean differences from pre-PR at peak exercise in 1) minute ventilation (VE) (P=0.004), VO2 (P<0.0001), and carbon dioxide output (VCO2) (P<0.0001) were lower, 2) VE/VO2 (P=0.034) and VE/VCO2 (P=0.006) were higher, and 3) the dead space/tidal volume ratio (VD/VT) and the dyspnea level were similar. After PR, there was no significant difference in the ratio of the observed peak heart rate (HR) to the predicted peak HR (220 – age [years]) between the two groups. A significant negative correlation with the baseline time–slope (r=-0.496, P=0.002) and a positive correlation with the baseline body mass index (BMI) (r=0.496, P=0.002) were obtained. Conclusions: PR in COPD patients improves Tex rather than exercise tolerance, economizing oxygen requirements, resulting in reduced ventilatory requirements without cardiac loads followed by reduced exertional dyspnea. In addition, the time–slope and BMI could be used to predict PR responses beforehand.

18 October 2011 in Respirology
Verified
Journal Article
Closed access
PDF file
KMKeisuke Miki
Keisuke Miki
RMRyoji Maekura
Ryoji Maekura
THToru Hiraga
Toru Hiraga
SKSeigo Kitada
Seigo Kitada
MMMari Miki
Mari Miki
YTYoshitaka Tateishi
Yoshitaka Tateishi